Read by QxMD icon Read

Lymphocytic leukemia

Akihiko Yuki, Satoru Shinkuma, Ryota Hayashi, Hiroki Fujikawa, Taisuke Kato, Erina Homma, Yohei Hamade, Osamu Onodera, Masao Matsuoka, Hiroshi Shimizu, Hiroaki Iwata, Riichiro Abe
BACKGROUND: Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL). Early-stage MF patches or plaques often resemble inflammatory skin disorders (ISDs), including psoriasis and atopic dermatitis. Cell adhesion molecule 1 (CADM1), initially identified as a tumor suppressor gene in human non-small-cell lung cancer, has been reported as a diagnostic marker for adult T-cell leukemia/lymphoma (ATLL). OBJECTIVE: We investigated CADM1 expression in MF neoplastic cells, especially during early stages, and evaluated its usefulness as a diagnostic marker for MF...
June 18, 2018: Journal of the American Academy of Dermatology
Dominik Dłuski, Dorota Lewkowicz, Bożena Leszczyńska-Gorzelak, Bogdan Obrzut, Tomasz Rechberger, Andrzej Semczuk
Introduction: The coexistence of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with different gynecologic neoplasms is a rare phenomenon. Here, we report a case of simultaneously developed CLL/SLL with endometrioid-type uterine cancer. Case Report: A 58-year-old woman was admitted to the 2nd Department of Gynecology, Lublin Medical University, Lublin, Poland, in June 2017, where the uterine cancer was diagnosed. After the surgery, pathological examination revealed a uterine moderately differentiated adenocarcinoma of endometrioid subtype (subtype I according to Bokhman) deeply infiltrating the myometrium as well as the uterine cervix...
May 2018: Case Reports in Oncology
Monica Poveste, Franziska Meinzer, Percy Lehmann, Thomas Mentzel, Silke C Hofmann
No abstract text is available yet for this article.
June 21, 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Viktor Schneidt, Marta Ilecka, Peter Dreger, Dwain G van Zyl, Susanne Fink, Josef Mautner, Henri-Jacques Delecluse
Chronic lymphocytic leukemia (CLL) is the most frequent B cell malignancy in Caucasian adults. The therapeutic armamentarium against this incurable disease has recently seen a tremendous expansion with the introduction of specific pathway inhibitors and innovative immunotherapy. However, none of these approaches is curative and devoid of side effects. We have used B-cell-specific antibodies conjugated with antigens (AgAbs) of the Epstein-Barr virus (EBV) to efficiently expand memory CD4+ cytotoxic T lymphocytes (CTLs) that recognized viral epitopes in 12 treatment-naive patients with CLL...
June 20, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Serena De Matteis, Chiara Molinari, Giulia Abbati, Tania Rossi, Roberta Napolitano, Martina Ghetti, Andrea Ghelli Luserna Di Rorà, Gerardo Musuraca, Alessandro Lucchesi, Gian Matteo Rigolin, Antonio Cuneo, Daniele Calistri, Pier Paolo Fattori, Massimiliano Bonafè, Giovanni Martinelli
BACKGROUND: In chronic lymphocytic leukemia (CLL) disease onset and progression are influenced by the behavior of specific CD4+ T cell subsets, such as T regulatory cells (Tregs). Here, we focused on the phenotypic and functional characterization of Tregs in CLL patients to improve our understanding of the putative mechanism by which these cells combine immunosuppressive and effector-like properties. METHODS: Peripheral blood mononuclear cells were isolated from newly diagnosed CLL patients (n = 25) and healthy volunteers (n = 25)...
June 20, 2018: Journal of Translational Medicine
Ceren Hangül, Orhan Kemal Yücel, Bahar Akkaya, Levent Ündar, Sibel Berker Karaüzüm
No abstract text is available yet for this article.
June 20, 2018: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
Tim R de Back, Arnon P Kater, Sanne H Tonino
Chronic lymphocytic leukemia (CLL) is frequently complicated by cytopenias, either due to bone marrow infiltration or autoimmunity, resulting in autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cell aplasia (PRCA) or autoimmune neutropenia (AIN). Morbidity due to autoimmune cytopenias (AIC) can be substantial; in addition, infection risk increases and pre-existing infections might deteriorate due to immunosuppressive medication. In the aging population, CLL occurs more frequently and AIC related to CLL represent a growing clinical challenge...
June 20, 2018: Expert Review of Hematology
Xinke Zhang, Xue Song, Lorena Lopez-Gonzalez, Krutika Jariwala-Parikh, Ze Cong
BACKGROUND: Infections, cytopenia, and gastrointestinal (GI) toxicity are adverse events of special interest (AESI) affecting most relapsed Philadelphia chromosome-negative (Ph-) B-cell acute lymphocytic leukemia (ALL) patients. This study quantified real-world rates and economic burden of these events among relapsed Ph- B-cell ALL patients in the US. RESEARCH DESIGN AND METHODS: Adults with relapsed Ph- B-cell ALL during 4/1/2009 - 10/31/2016 were selected from MarketScan® healthcare claims databases...
June 20, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
G Shi, C M Hu, Q Yu, N Yang, Z S Xue, B Zhao, M Guo, Y Zheng
Pure red cell aplasia (PRCA) develops as a result of erythroid precursors failing to reach maturity in the bone marrow, which eventually leads to anemia. Here we present a case of a 64-year-old Asian male with a medical history of colorectal adenocarcinoma who had been treated with 6 cycles of oxaliplatin and capecitabine four years ago. The patient was diagnosed with PRCA and T-cell large granular lymphocyte leukemia.
May 2018: Journal of Biological Regulators and Homeostatic Agents
Christine I Chen, Harminder Paul, Lisa W Le, Ellen N Wei, Susi Snitzler, Trina Wang, Olga Levina, Sumeet Kakar, Anthea Lau, Michelle Queau, James B Johnston, Deborah A Smith, Suzanne Trudel
AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic leukemia (CLL). In this phase 2 trial, 30 relapsed/refractory CLL patients were treated with combination afuresertib, a novel oral AKT inhibitor, and ofatumumab for 6 months, followed by afuresertib maintenance for 12 months. We aimed to achieve deeper and more durable responses, without requiring long-term continuous treatment. Treatment was generally well tolerated but respiratory infections were common, with 18% severe requiring hospitalization...
June 19, 2018: Leukemia & Lymphoma
Lorenzo Bordini, Giuseppe Taino
OBJECTIVES: Stochastic effects induced by exposure to ionizing radiation rapresent a relevance radioprotection aspect. METHODS: Actually most of the information about radiation-induced oncogenic risk arise from the follow-up of the atomic bombs survivors (Life Span Study, LSS); at this information sources have been added over the last decades also data derived from medical, occupational and environmental studies conducted in various parts of the world and their contribution about number of cases and duration of follow-up period is of great relevance...
November 2017: Giornale Italiano di Medicina del Lavoro Ed Ergonomia
Timothy M Pierpont, Candice B Limper, Kristy L Richards
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval in 1997, it has improved outcomes in all B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from in vitro studies while the roles of the various response mechanisms in humans are still largely undetermined...
2018: Frontiers in Oncology
Tomohiro Okagawa, Satoru Konnai, Asami Nishimori, Naoya Maekawa, Shinya Goto, Ryoyo Ikebuchi, Junko Kohara, Yasuhiko Suzuki, Shinji Yamada, Yukinari Kato, Shiro Murata, Kazuhiko Ohashi
Bovine leukemia virus (BLV) is a retrovirus that infects B cells in cattle and causes bovine leukosis after a long latent period. Progressive exhaustion of T cell functions is considered to facilitate disease progression of BLV infection. Programmed death-1 (PD-1) and lymphocyte activation gene-3 (LAG-3) are immunoinhibitory receptors that contribute to T-cell exhaustion caused by BLV infection in cattle. However, it is unclear whether the cooperation of PD-1 and LAG-3 accelerates disease progression of BLV infection...
June 19, 2018: Veterinary Research
Kyle Crassini, Tahni Pyke, Yandong Shen, William S Stevenson, Richard I Christopherson, Stephen P Mulligan, Oliver Giles Best
The Raf-1 kinase inhibitory protein (RKIP) is an important regulatory element in multiple signaling pathways, including MAPK-ERK1/2. We investigated whether targeted disruption of RKIP is a therapeutic option for chronic lymphocytic leukemia (CLL). The RKIP inhibitor locostatin-induced apoptosis of CLL cells, irrespective of poor prognostic indications or treatment history. Locostatin down-regulated MAPK-ERK1/2 and AKT phosphorylation, decreased expression of the chemokine receptor CXCR4 (p = .04) and reduced the migratory capacity of CLL cells toward stroma-derived factor 1α (SDF-1α, p = ...
June 18, 2018: Leukemia & Lymphoma
Paolo Strati, Cristina Gabutti, Philip A Thompson, Dimitrios P Kontoyiannis, Alessandra Ferrajoli
No abstract text is available yet for this article.
June 18, 2018: Leukemia & Lymphoma
Sotirios G Papageorgiou, Marios A Diamantopoulos, Christos K Kontos, Anthi Bouchla, Diamantina Vasilatou, Efthymia Bazani, Andreas Scorilas, Vasiliki Pappa
MicroRNA-92a-3p (miR-92a-3p) is a member of the miR-17/92 cluster and the cancer-related miR-92 family. miR-92a-3p regulates important transcription factors such as hypoxia-inducible factor 1 (HIF1) and inhibits SOCS1 to enhance the anti-apoptotic STAT3/IL6 signaling route. In this study, we examined the putative prognostic value of miR-92a-3p in chronic lymphocytic leukemia (CLL). Total RNA, which was isolated from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 non-leukemic blood donors, was polyadenylated and reverse-transcribed...
June 18, 2018: Leukemia & Lymphoma
Mark B Geyer, Isabelle Rivière, Brigitte Sénéchal, Xiuyan Wang, Yongzeng Wang, Terence J Purdon, Meier Hsu, Sean M Devlin, Elizabeth Halton, Nicole Lamanna, Jurgen Rademaker, Michel Sadelain, Renier J Brentjens, Jae H Park
Patients with residual chronic lymphocytic leukemia (CLL) following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies. We and others have previously described the safety and efficacy of autologous T cells modified to express anti-CD19 chimeric antigen receptors (CARs) in patients with relapsed or refractory B cell acute lymphoblastic leukemia and CLL. Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab...
June 14, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
Sophia Danhof, Michael Hudecek, Eric L Smith
Harnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclinical investigation. Most recent clinical protocols have focused on targeting B-cell maturation antigen (BCMA), and early results are promising...
June 2018: Best Practice & Research. Clinical Haematology
Mohsen Abdolmaleki, Nazanin Mojtabavi, Mahdi Zavvar, Mohammad Vaezi, Farshid Noorbakhsh, Mohammad Hossein Nicknam
T cell exhaustion is an immunosuppressive mechanism which occurs in chronic viral infections, solid tumors and hematologic malignancies. Exhausted T cell has increased the expression of inhibitory receptors, and functional impairment. In this study, we investigated the expression from some of those inhibitory receptors being Programmed death 1 (PD-1), T cell immunoglobulin and mucin domain containing molecules 3 (TIM-3) and CD244 on T cells from Iranian acute myeloid leukemia (AML) patients. Peripheral blood samples were collected from Iranian newly diagnosed AML patients and flow cytometric analysis was accomplished for cell surface expression of PD-1, TIM-3, and CD244 on T lymphocytes...
June 2018: Iranian Journal of Allergy, Asthma, and Immunology
Maïlys Le Guyader, Marie Coude, Kamel Laribi, Anne Besançon, Habib Ghnaya, Nathalie Denizon, Sabine Defasque, Fabienne Pineau-Vincent, Mohamed Kaabar, Pierre Lemaire
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm defined by the presence of at least 5×109 G/L monoclonal B lymphocytes in the peripheral blood. It is the most common type of leukemia in adult patients from Western countries. CLL is characterized by a gradual accumulation of small, longliving, immunologically dysfunctional, morphologically mature-appearing B-lymphocytes in blood, bone marrow and lymphoid tissues. It has also been reported that CLL cells have a proliferation rate higher than previously recognized, particularly in the lymphoid tissues...
June 15, 2018: Annales de Biologie Clinique
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"